Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
22 Fevereiro 2024 - 9:00AM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field
of cellular metabolism pioneering therapies for rare diseases,
today announced that the company is scheduled to present at the TD
Cowen 44th Annual Health Care Conference on Monday, March 4, 2024,
at 2:10 p.m. ET.
A live webcast of the presentation can be accessed
under "Events & Presentations" in the Investors section of the
company's website at www.agios.com. A replay of the webcast will be
archived on the company’s website for at least two weeks following
the presentation.
About AgiosAgios is the pioneering
leader in PK activation and is dedicated to developing and
delivering transformative therapies for patients living with rare
diseases. In the U.S., Agios markets a first-in-class pyruvate
kinase (PK) activator for adults with PK deficiency, the first
disease-modifying therapy for this rare, lifelong, debilitating
hemolytic anemia. Building on the company's deep scientific
expertise in classical hematology and leadership in the field of
cellular metabolism and rare hematologic diseases, Agios is
advancing a robust clinical pipeline of investigational medicines
with programs in alpha- and beta-thalassemia, sickle cell disease,
pediatric PK deficiency, MDS-associated anemia and phenylketonuria
(PKU). In addition to its clinical pipeline, Agios is advancing a
preclinical TMPRSS6 siRNA as a potential treatment for polycythemia
vera. For more information, please visit the company’s website at
www.agios.com.
Contacts:
Investor ContactChris Taylor, VP, Investor
Relations and Corporate CommunicationsAgios
PharmaceuticalsIR@agios.com
Media Contact Dan Budwick1AB
dan@1abmedia.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024